Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

Journal of Clinical Oncology

Volumn 19, Issue 13, 2001, Pages 3234-3243

  Robert, F ^a   Ezekiel, M P ^a   Spencer, S A ^a   Meredith, R F ^a   Bonner, J A ^a   Khazaeli, M B ^a   Saleh, M N ^a   Carey, D ^a   Lobuglio, A F ^a   Wheeler, R H ^a   Cooper, M R ^a   Waksal, H W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HEAD CANCER; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NECK CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIOMETRY; SKIN MANIFESTATION; SKIN TOXICITY; XEROSTOMIA;

EID: 0035398021     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.13.3234     Document Type: Article

References (44)

1. Conventional therapy of head and neck
2. Recent advances in radiation therapy for head and neck cancer
3. Characterization of radiation sensitivity of human squamous carcinoma A431 cells
4. The hazard of accelerated tumor clonogen repopulation during radiotherapy
5. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy
6. Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: Preliminary report of Radiation Therapy Oncology Group protocol 83-13
7. Concomitant boost radiotherapy schedule in the treatment of carcinoma of the oropharynx and nasopharynx
8. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma
9. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy in head and neck squamous cell carcinoma: First report of RTOG 9003
10. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial
11. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer
12. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
13. Expression of epidermal growth factor receptor in laryngeal dysplasia and carcinoma
14. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma
15. Characterization, quantification, and potential clinical value of epidermal growth factor receptor in head and neck squamous cell carcinoma
16. Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumors
17. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
18. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer
19. Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation
20. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation
21. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities
22. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
23. Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852
24. Growth stimulation of A431 cells by EGF: Identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody
25. Monoclonal antiepidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity
26. Biological effect in vitro of monoclonal antibodies to human EGF receptors
27. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells
28. Biological efficacy of a chimeric antibody to the epidermal growth factor in a human tumor xenograft model
29. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
30. Epidermal growth factor receptor family and chemosensitization
31. Combined modality therapy of A431 human epidermal cancer using anti-EGFr antibody C225 and radiation
32. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
33. Staging of cancer of specific anatomic sites: Head and neck
34. Quantitation of mouse monoclonal antibody and human anti-mouse antibody response in serum of patients
35. Human immune response to monoclonal antibodies
36. Nonparametric estimation from incomplete observations
37. Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: An EORTC randomized trial
38. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy in stages III and IV oropharynx carcinoma: Preliminary results of the 94.01 study from the French Group of Radiation Oncology for Head and Neck Cancer
39. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with Cisplatin
40. Twice a day versus once a day radiation therapy in head and neck cancer
41. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer
42. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099
43. An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer
44. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data